T56-LIMKi是一种选择性LIMK2抑制剂，抑制Panc-1细胞生长的IC50值为35.2 μM。

T56-LIMKi is a selective inhibitor of LIMK2.

T56-LIMKi efficiently inhibits the growth of ST88-14, U87, Panc-1 cells, A549 lung cancer cells with IC50 values of 18.3, 7.4, 35.2 and 90 μM, respectively. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and accordingly inhibits the growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma[1]. It blocks the phosphorylation of cofilin which leads to actin severance and inhibition of tumor cell migration, tumor cell growth, and anchorage-independent colony formation in soft agar. T56-LIMKi (10-50 μM) reduces p-cofilin in a dose-dependent manner in NF1–/–MEFs with an IC50 of 30 μM. Notably, the inhibitor does not affect the amounts of total cofil. 50 μM T56-LIMKi causes a statistically significant reduction in the number of cells exhibiting stress fibers[2].

T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) display a significant decrease in tumor volume than controls[1].

T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control[1].

924473-59-6

C19H14F3N3O3

389.33

T5601640

DMSO:36 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years